Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

About this update from Kuros Biosciences Ltd.

[{"type":"image","alt":"Kuros Biosciences AG","displaySize":"","headline":null,"caption":"Kuros Biosciences AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":53,"url":"https://media.zenfs.com/en/globenewswire.com/806763a848369caf74ba90fee6846b72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AuUNwyHGpxCZyeU5qoHMeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/806763a848369caf74ba90fee6846b72","width":300,"height":53}},"lazy":false},{"type":"text","content":"Ad-hoc announcement pursuant to Article 53 of the SIX listing rules","length":67,"tagName":"p"},{"type":"text","content":"Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025","length":95,"tagName":"p"},{"type":"text","content":"Financial Highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total Medical Device sales rose by 72%, or USD 60.9 million, to USD 146.1 million (2024: USD 85.2 million)","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Direct MagnetOs™ sales increased by 71% to USD 143.9 million (2024: USD 84.3 million)","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Total Group EBITDA reached USD 12.4 million (2024: USD 2.4 million)","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Total Group adjusted EBITDA* arrived at USD 19.6 million, resulting in a margin of 13.4% (2024: USD 10.1 million at 11.9%)","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"For the first time in the company’s history, the Group delivered a net profit of USD 2.6 million (2024: net loss of USD (4.8) million)","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents stood at USD 19.8 million, reflecting a strong operational cash flow generation allowing for continued substantial investments in working capital and the new U.S. production facility (2024: USD 19.8 million)","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"The Group expects at least 35% sales growth in 2026, with an adjusted EBITDA margin of around 14%. By 2028, the Group anticipates sales of USD 300 to 330 million with an adjusted EBITDA margin of at least 20%","length":208,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":955,"olType":false},{"type":"text",...

More updates from Kuros Biosciences Ltd.